Abstract
Up to now the exstirpation of thymus gland stands in the central position of the immuno-therapeutic strategy of myasthenia gravis promising alone the chance of total and definitive recovery in some cases. FIGURE 1. The current antigen-specific therapeutical approaches inducing autoimmune unresponsiveness to acetylcholin receptor are still in experimental phase.(ref. 1) They certainly need a rather long period until one or more of them will be applied in humans. This is the reason why the therapeutic centers elaborated new management for the therapy-resistant patients.(ref. 2, 3, 4, 5). FIGURE 2. In some dubious cases the diagnosis of myasthenia gravis and the indication of thymectomy are difficult and need a long-lasting observation. The benefit from maintaining anticholinesterase therapy, the significant respond to plasma-exchange in crisis, the secondary generalization of ocular symptoms and the electrodiagnostic tests becoming positive after some years all strengthen the indication for thymectomy. FIGURE 3. As you can see on the third figure the indication of immunotherapies other than thymectomy has pro- and contra-arguments. We used to apply these methods at thymectomy unresponders, elderly X-ray unresponders, pregnants in crisis-prone state and in anticholinesterase resistance or intolerance. The crisis tendency is the major reason for applying these expensive therapies, but decreasing the drug doses and making rare the myasthenic relapses in the interest of improving life-quality are not negligible standpoints, either. FIGURE 4. In some severe cases both the plasma-exchange and the high-dose intravenous methylprednisolon infusion as well as the repeated high-dose intravenous immunoglobulin therapy may unfortunately fail.(ref. 6, 7, 8) All these observations induced us preparing new effectual therapeutic pattern.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Drachman D.B., K.R. Mclntosh, J. Reim, L. Balcer. 1993. Strategies for treatment of myasthenia gravis. Ann.N.Y.Acad.Sci. 681:515–528.
Åhlberg R., Q. Yi, R. Pirskanen, G. Matell, C. Swerup, P. Rieber, G. Riethmüller, G. Holm, A.K. Lefvert. 1993. Clinical improvement of myasthenia gravis by treatment with a chimeric anti-CD-4 monoclonal antibody. Ann.N.Y.Acad.Sci. 681:552–555.
Arsura E., N.G. Brunner, T. Namba, D. Grob. 1985. High-dose intravenous methylprednisolone in myasthenia gravis. Arch. Neurol. 42:1149–1153.
Devathasen G., Y.K. Kuch, P.N. Chong. 1984. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 2:809.
Fateh-Moghadam A., M. Wock, U. Besinger, R.G. Geursen. 1984. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 2:848.
Fornádi L., R. Horváth, A. Szobor. 1991. Treatment with plasma-exchange. Experiences over ten years. Acta Med. Hung. 48:137–144.
Kornfeld P., S. Fox, K. Maier, M. Mahjoub. 1992. Ten years experience with therapeutic apheresis in a community hospital. J. Clin. Apher. 7:63–68.
Fornádi L., R. Horváth, Z. Bárdosi, A. Szobor. 1994. Myasthenia gravis: effect of immunoactive therapies. Acta Med. Hung. 50:83–92.
Szobor A. 1990. Myasthenia gravis, pp. 120-143, 147-152, 154-189. Akadémiai kiadó, Budapest.
Szobor A., J. Molnár. 1990. Myasthenia gravis: results of thymectomy in 550 patients. Orv. Hetil. 131:2519–2527.
Szobor A. 1977. Pathomechanismen myasthenischer Krisenzustände. In: Schulze A.F., K. Seidel, S. Göllnitz (eds): Akute Krisenzustände und Notsituationen in der Neurologie und Psychiatrie. S. 7-10. Hirzel, Leipzig.
Cornelio F., C. Antozzi, R. Mantegazza, P. Confalonieri, E. Berta, D. Peluchetti, A. Sghirlanzoni, F. Fiacchino. 1993. Immunosuppressive treatments. Their efficacy on myasthenia gravis patients’ outcome and on the natural course of the disease. Ann. N.Y.Acad.Sci. 681:594–602.
Vincent A., Z. Li, A. Hart, R. Barrett-Jolley, T. Yamamoto, J. Burges, D. Wray, N. Byne, P. Molenaar, J. Newsom-Davis. 1993. Seronegative myasthenia gravis. Evidence for plasma factor/s) interfering with acetylcholin-receptor function. Ann.N.Y.Acad.Sci. 681:529–538.
Tindall R.S.A., J.T. Phillips, J.A. Rollins, L. Wells, K. Hall. 1993. A clinical therapeutic trial of Cyclosporine in myasthenia gravis. Ann.N.Y.Acad.Sci. 681:539–551.
Tan E., M. Hajinazarian, W. Bay, J. Neff, J.R. Mendell. 1993. Acut renal failure resulting from intravenous immunoglobuline therapy. Arch. Neurol. 50:135–139.
Szobor A. 1976. Myasthenia gravis: A quantitative evaluation system. Disability Status Scale/DSS) applied for myasthenia gravis. Eur.Neurol. 14:439–446.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Fornádi, L., Horváth, R., Szobor, A. (1997). Management of Thymectomized Myasthenic Patients. In: Marx, A., Müller-Hermelink, H.K. (eds) Epithelial Tumors of the Thymus. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0033-3_48
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0033-3_48
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0035-7
Online ISBN: 978-1-4899-0033-3
eBook Packages: Springer Book Archive